My lack of understanding [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2010-05-29 05:32 (5500 d 15:29 ago) – Posting: # 5397
Views: 16,827

Hi Gstats,

❝ And we can use Baseline response in the absence of the drug as third dose level and make a fair fit to that model for ref.


I am afraid I am not able to see the practical applicability of that; for any data point associated with ref. there will be two dose levels, or perhaps three if you're right this will only be the case if we assume Emin is the same for both test and ref. (reasonable, if you ask me) and equal to the effect at run-in. The latter lacks qualification and I would really be surprised if the FDA would allow that kind of assumption. It would not fit into my image of those gents.


Mystified and still curious to see how this would work in practise.
EM.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,676 registered users;
37 visitors (0 registered, 37 guests [including 10 identified bots]).
Forum time: 21:01 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5